Novel Wireless Device Uses Light to Send Information Directly to the Brain

Chemotherapy-free regimen could be new standard in Ph+ acute lymphoblastic leukemia

ORLANDO — A chemotherapy-free regimen significantly improved outcomes compared with standard therapy for newly diagnosed Ph+ acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.Patients who received ponatinib (Iclusig, Takeda) and blinatumomab (Blincyto, Amgen) achieved higher rates of clinical hematologic remission and minimal residual

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study.

Chemo-Free Ponatinib/Blinatumomab Improves Survival in Ph+ ALL | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

A New Option Without Traditional Chemotherapy for Ph+ ALL

A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.

Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL

Clinical efficacy and response rates were increased with blinatumomab/ponatinib vs chemotherapy/imatinib for patients with Ph+ ALL.